Early breast cancer patients with low levels of HER2 expression benefit more from the cancer vaccine E75

By  

Inpharma, Vol. 1, Iss. 1635, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Serum Her-2/neu and Survivin Levels and Their Relationship to Histological Parameters in Early-stage Breast Cancer

By Goksel G   Taneli F   Uslu R   Ulman C   Dinc G   Coskun T   Kandiloglu AR  

The Journal of International Medical Research, Vol. 35, Iss. 2, 2007-03 ,pp. : 165-172

Field House Publishing

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

Enrolment has commenced for a new phase I trial evaluating the combination of AE 37 and another HER-2/neu-based cancer vaccine

By  

Inpharma, Vol. 1, Iss. 1651, 2008-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Correlation Between the In Vitro ATP-based Chemosensitivity Assay and HER2/neu Expression in Women with Breast Cancer

By Woo SU   Bae JW   Kim HG   Choi SH   Kang DH   Lee JB   Koo BW  

The Journal of International Medical Research, Vol. 35, Iss. 6, 2007-11 ,pp. : 753-761

Field House Publishing

Access to resources Recommend Favorite